Biotech Archives - Page 32 of 795

1 minute read

Apogee Doses First Patient In Phase 2 Atopic Dermatitis Trial Of APG777 For The Treatment Of Atopic Dermatitis And Other Inflammatory Diseases

May 15, 4:18 PM

Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of approximately 75 days with a potentially best-in-class profile 16-week proof-of-concept

APGE

2 minute read

Galapagos And Blood Centers Of America Collaborate To Expand Galapagos’ Decentralized CAR-T Manufacturing Network In The U.S.

By Benzinga Newsdesk

May 15, 4:03 PM

BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centersCollaboration enables rapid deployment of Galapagos'

GLPG

2 minute read

Takeda’s Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement

By Vandana Singh

May 15, 2:02 PM

Takeda's dengue vaccine, Qdenga, gains WHO prequalification, enabling UN agency procurement. Approved in multiple countries, Qdenga is recommended for children 6-16 in high dengue areas.

SNY

1 minute read

Phio Pharmaceuticals Completes Dosing In First Patient Cohort In PH-762 Phase 1b Dose-Escalation Study

By Benzinga Newsdesk

May 15, 1:02 PM

-PH-762 is Phio's lead product candidate -Screening on the next cohort is on-goingMARLBOROUGH, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company

PHIO

2 minute read

No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms

By Vandana Singh

May 15, 11:59 AM

Novo Nordisk confirms there is no anticipated shortage of Wegovy in Denmark, despite prior warnings from the Danish Medicines Agency about limited supplies. The company addresses high demand and reassures the availability of all doses.

LLY

2 minute read

FDA Pushes Review Date For Ascendis Pharma’s Hormone Disorder Candidate By Three Months

By Vandana Singh

May 15, 11:57 AM

Ascendis Pharma announces FDA's extension of the review date for TransCon PTH for adults with hypoparathyroidism to August 14, 2024. TransCon PTH aims to address low calcium levels due to hypoparathyroidism.

ASND

2 minute read

Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound

By Vandana Singh

May 15, 10:03 AM

Eli Lilly has settled with Totality Medispa over counterfeit Mounjaro and Zepbound sales. The spa will pay damages and cease using Lilly branding. Corrective measures include compliance with federal law for tirzepatide products.

LLY

1 minute read

Pulmatrix Announces Peer-Reviewed Publication Headache: The Journal Of Head And Face Pain, Clinical Results For Its Orally Inhaled DHE For Acute Migraine

By Benzinga Newsdesk

May 15, 9:31 AM

Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) administered DHE.Self-administered PUR3100 showed improved safety and

PULM

1 minute read

Butterfly Network Enters Bladder Scanning Market With iQ+ Bladder

By Benzinga Newsdesk

May 15, 8:35 AM

With iQ+ Bladder, Butterfly expands outside its core point-of-care ultrasound market to better serve the bladder scanning market with its proprietary Ultrasound-on-Chip™ technology.The bundled bladder solution

BFLY

1 minute read

Phathom Pharmaceuticals Will Present VOQUEZNA Data At DDW 2024 Annual Meeting, Being Held May 18-21

By Benzinga Newsdesk

May 15, 8:07 AM

First oral presentation of Phase 3 data evaluating the investigational use of VOQUEZNA® in Non-Erosive Reflux Disease (NERD)1 New research on Erosive gastroesophageal reflux disease (GERD) demonstrating high

PHAT